The healthcare market access environment has changed significantly in the last five years. National governments, payers and value assessors want to secure timely access to innovative treatments for patients, whilst ensuring the continued sustainability of healthcare systems. There is more pressure on pharmaceutical companies to demonstrate the value of a product for patients and society when attempting to launch in national markets.
Companies are being asked for additional post-marketing authorisation data and are regularly exploring managed entry agreements with national payers and governments – in some cases proactively proposing an agreement before the pricing and reimbursement negotiations begin.
More regular engagement, earlier in the drug development cycle is leading to an overlap in interests, with regulators looking at access challenges and HTA bodies looking at budget impact.
To adapt, companies need compelling arguments about the value and affordability of their treatments. Communications, patient advocacy and on-going stakeholder engagement help manage expectations and alignment of audiences, should pricing and reimbursement processes prove challenging.
Hanover provides clients with a range of combined public affairs, patient advocacy and market access services that help to shape the external environment to facilitate patient access to treatment. Our International Policy and Market Access team combines expertise in public policy, patient advocacy and communications. The team has a proven track record in working on regional, international and global projects with not-for profit and for industry clients
If you would like to discuss how we could help, please contact: